Satellos Bioscience (MSLE) Payables (2023 - 2026)

Satellos Bioscience (MSLE) posted quarterly Payables of $4.6 million for Q1 2026, up 11.16% quarter-over-quarter from $4.1 million in Q4 2025.

Satellos Bioscience (MSLE) Payables (2023 - 2026) Analysis & Trends

Satellos Bioscience (MSLE) has reported Payables for 4 consecutive years, with $4.6 million the latest figure, recorded in Q1 2026.

In Q1 2026, Payables changed N/A year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $4.6 million (changed N/A YoY), while the FY2025 annual figure was $4.1 million, up 11.24% from the prior year.
Payables advanced to $4.6 million in Q1 2026 per MSLE's latest filing, from $4.1 million in the prior quarter.
Across five years, Payables topped out at $4.6 million in Q1 2026 and bottomed at $2.7 million in Q4 2023.
Historically, Payables has averaged $3.8 million across 4 years, with a median of $3.9 million in 2024.
Annual changes were most pronounced in 2024 — Payables jumped 38.63% — and 2025, when it climbed 11.24%.
Satellos Bioscience's Payables stood at $2.7 million in 2023, then soared by 38.63% to $3.7 million in 2024, then gained by 11.24% to $4.1 million in 2025, then climbed by 11.16% to $4.6 million in 2026.
Business Quant data shows MSLE's Payables at $4.6 million in Q1 2026, $4.1 million in Q4 2025, and $3.7 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Payables (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	429.50 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.16 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.52 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	167.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	470.30 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	108.02 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	428.93 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	35.57 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	622.65 Mn
10	Satellos Bioscience	208.31 Mn	208.31 Mn	-	5.86 Mn

Download Data